Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Okta, Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Okta, Inc. trades at $209.1 (market cap $39.60B). The key difference: Okta, Inc. is far larger — about 4.5× Kymera Therapeutics Inc. Common Stock's market cap, and Okta, Inc. is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Okta, Inc. for 44 Days on average.
| KYMR | OKTA | |
|---|---|---|
Market Cap | $8.87B | $39.60B |
Volume | 779,107 | 2,315,203 |
Sector | Health | Technology |
52-Week High | $127.31 | $232.13 |
52-Week Low | $55.80 | $62.93 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $8.26B | $37.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKTA trades at $211.92, down 6.68% today, but maintains strong analyst support with 74% buy ratings and a consensus price target of $201.76. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $0.93. Revenue growth remains robust, climbing from $1.3B in 2022 to $2.6B in 2025, while achieving positive net income of $28M after years of losses. Technical indicators show a bullish trend with key support at $215.
OKTA presents a compelling growth story with improving profitability and strong positioning in identity management. The stock faces valuation concerns with a P/E of 136, but AI security initiatives and consistent earnings beats provide catalysts. Key risks include high valuation multiples and competitive pressures in cybersecurity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
